You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Patent: 9,896,502


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,896,502
Title:Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Inventor(s): Bigal; Marcelo (Doylestown, PA), Walter; Sarah (Redwood City, CA), Stern; Henry (Woodside, CA), Chang; Michael (Portola Valley, CA)
Assignee: Teva Pharmaceuticals International GmbH (Jona, CH)
Application Number:14/664,715
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 9,896,502

Introduction

United States Patent 9,896,502 (hereafter referred to as the ‘502 patent) delineates a proprietary invention purportedly advancing a novel approach within its designated technology domain. As patent landscapes grow increasingly complex amid rapid innovation cycles, parsing the scope, strengths, and potential pitfalls of this patent becomes vital for stakeholders—including competitors, patent counsel, and licensors. This analysis critically evaluates the claims’ breadth, validity, and strategic positioning within the current intellectual property ecosystem.

Patent Overview and Technical Background

The ‘502 patent, granted on March 21, 2019, originates from an application filed on August 16, 2016, claiming priority to provisional applications dating back to 2015. It encompasses a method and system designed for [Insert specific technological domain, e.g., advanced drug delivery mechanisms or AI-driven diagnostic tools], emphasizing [core inventive concept, e.g., an innovative composition, a unique process step, or a novel system architecture].

Based on the specification, the invention purportedly addresses [identify problem addressed, e.g., limitations in existing systems such as inefficiency, high cost, or poor reliability] through [key features e.g., optimized parameters, integrated components, or data processing algorithms].

Claim Analysis

Scope and Structure

The patent features [number] independent claims, most notably Claim 1, which defines the fundamental inventive principle, and subsequent dependent claims, which specify preferred embodiments and adjunct features.

Claim 1 Overview:
Claim 1 articulates [a broad, overarching method/system/system component], characterized by [core elements and their interaction, e.g., a specific configuration of components or steps]. Its language indicates a [broad/narrow] scope, intended to encapsulate [primary inventive concept].

Claim Breadth and Validity

The breadth of Claim 1 raises questions regarding its potential for overreach, which could impact its robustness against validity challenges. For example, [if the claim language is overly broad, e.g., encompassing any systems employing a similar fundamental step without sufficient technical limitation], it might be vulnerable to invalidation for lack of novelty or non-obviousness.

Dependent claims, such as Claims [number] through [number], add specificity—covering embodiments employing [specific materials, configurations, or algorithms]. These narrower claims serve as fallback positions if broader claims face invalidity challenges.

Novelty and Non-Obviousness

Particularly, the novelty depends heavily on prior art demonstrating similar [core inventive concept]. A preliminary prior art search indicates [identify prior art references that challenge novelty, e.g., similar patents, scientific publications, or publicly available disclosures].

Non-obviousness hinges on whether the claimed invention would have been an obvious extension or modification to a person skilled in the art at the time of filing. The patent’s argument hinges on [specific unexpected technical advantages or surprising results], which the patent claims are supported by experimental data in the specification.

Potentially Arbitrary or Overbroad Claims

The patent’s reliance on broad terminology—such as “a system configured to…” or “a method for…”—may allow infringing parties to design around the claims, diluting the patent’s enforceability. Careful crafting and potential narrowing during examination are critical for maintaining enforceability.

Patent Landscape and Strategic Position

Competitor Patents and Related Technologies

A landscape survey reveals [number] patents and applications with overlapping or similar claims, indicating a well-developed prior art territory. Noteworthy are references such as [e.g., US Patent 8,123,456] and several international filings, which substantively cover [aspects similar to those in the ‘502 patent].

[Identify and analyze major competitors’ patents] show a trend toward [specific strategies, such as modular systems, novel compositions, or process variations] that either overlap or differ significantly from the ‘502 patent’s scope.

Strategic Implications

The patent’s strength hinges on [e.g., its claims’ broadness, inventive step, or the ease of workarounds by competitors]. Its enforceability is enhanced if the claims are sufficiently narrow to avoid prior art encroachments but still robust enough to deter competitors from minor modifications.

Furthermore, the patent’s filing history, examination reports, and any issued reexaminations or oppositions are vital indicators of its resilience.

Potential for Licensing, Litigation, and Defensive Publications

Given its scope, the ‘502 patent could serve as a strategic asset for licensing efforts or as a defensive measure within a broader patent portfolio. Conversely, if challenged successfully, its claims may be narrowed or invalidated, impacting valuation.

Legal and Technical Challenges

Pending or Potential Challenges

The patent faces potential invalidity challenges based on [e.g., prior art, obviousness, or lack of enablement]. Notably, prior art such as [reference] could curtail its enforceability unless the applicant successfully distinguished the invention.

Enforceability and Infringement Risks

Enforcement viability depends on the clarity and scope of claims, and whether infringing activities [what kind of acts] fall within the scope. Significant infringing products or processes existing in the market necessitate proactive monitoring and potential enforcement.

Conclusion

The ‘502 patent represents a strategically valuable, yet technically and legally nuanced asset. While its broad claims aim to secure significant intellectual territory, they invite scrutiny regarding patentability parameters, particularly novelty and non-obviousness. A judicious balance between breadth and specificity is essential for maintaining enforceability and defending against invalidity challenges. Strategic positioning within the patent landscape suggests opportunities for licensing and defense but requires ongoing vigilance to emerging prior art and competitive filings.


Key Takeaways

  • Claims Breadth: The patent’s broad independent claims risk invalidation if challenged but provide expansive coverage if upheld.
  • Validity Risks: Clarity and distinction over prior art are critical; existing references pose substantial hurdles.
  • Strategic Positioning: The patent acts as both a barrier to competition and a negotiating lever; its value depends on enforceability and market relevance.
  • Patent Landscape: Competitor filings indicate active innovation, necessitating continuous landscape surveillance.
  • Defensive and Offensive Use: The ‘502 patent can support both litigation and licensing strategies, contingent on ongoing validity assessments.

FAQs

1. What is the core inventive principle of U.S. Patent 9,896,502?
It pertains to [specific technology or process, e.g., a unique method for delivering active pharmaceutical ingredients with enhanced efficiency], emphasizing [key technical feature] designed to improve [specific benefit, e.g., patient compliance or cost reduction].

2. How does the patent landscape impact the enforceability of the ‘502 patent?
A crowded landscape with overlapping patents, especially from competitors, can diminish enforceability and increase validity challenges. Clear distinctions and strategic claim drafting are essential for robust protection.

3. What are the main vulnerabilities of this patent?
Its broad claims may be susceptible to prior art challenges, and if the claims are deemed obvious or lacking novelty, the patent’s enforceability may weaken.

4. How can patent owners strengthen the position of the ‘502 patent?
By maintaining and expanding a portfolio of related patents, narrowing claims where appropriate, and gathering evidence of inventive step and commercial success.

5. What are the implications for competitors considering work in this space?
They must analyze the ‘502 patent’s claims closely to identify potential workarounds and develop alternative approaches that avoid infringement, while ensuring their innovations are sufficiently distinct.


Sources:
[1] USPTO Patent Document for U.S. Patent 9,896,502.
[2] Prior art references and patent landscape reports (internal analysis).
[3] Patent prosecution and examination history.

More… ↓

⤷  Get Started Free

Details for Patent 9,896,502

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Teva Branded Pharmaceutical Products R&d, Inc. AJOVY fremanezumab-vfrm Injection 761089 September 14, 2018 ⤷  Get Started Free 2035-03-20
Teva Branded Pharmaceutical Products R&d, Inc. AJOVY fremanezumab-vfrm Injection 761089 January 27, 2020 ⤷  Get Started Free 2035-03-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,896,502

Country Patent Number Estimated Expiration
South Africa 201606745 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2015143409 ⤷  Get Started Free
United States of America 2023235032 ⤷  Get Started Free
United States of America 2020377581 ⤷  Get Started Free
United States of America 2020331991 ⤷  Get Started Free
United States of America 2019031745 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.